PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Antipsychotics - Market size and forecast 2018-2023 • Non-antipsychotics - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Development of novel therapeutics • Increasing strategic alliances • Growing number of research studies to understand genetic root cause of • Tourette’s syndrome PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca Plc • Boehringer Ingelheim International GmbH • Eli Lilly and Co. • H. Lundbeck AS • Johnson & Johnson Services Inc. • Mylan NV • Otsuka Holdings Co. Ltd. • Pfizer Inc. • Sun Pharmaceutical Industries Ltd. • Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Antipsychotics - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Antipsychotics - Year-over-year growth 2019-2023 (%) Exhibit 22: Non-antipsychotics - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Non-antipsychotics - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Impact of drivers and challenges Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: AstraZeneca Plc - Vendor overview Exhibit 49: AstraZeneca Plc - Business segments Exhibit 50: AstraZeneca Plc - Organizational developments Exhibit 51: AstraZeneca Plc - Geographic focus Exhibit 52: AstraZeneca Plc - Key offerings Exhibit 53: AstraZeneca Plc - Key customers Exhibit 54: Boehringer Ingelheim International GmbH - Vendor overview Exhibit 55: Boehringer Ingelheim International GmbH - Business segments Exhibit 56: Boehringer Ingelheim International GmbH - Organizational developments Exhibit 57: Boehringer Ingelheim International GmbH - Geographic focus Exhibit 58: Boehringer Ingelheim International GmbH - Segment focus Exhibit 59: Boehringer Ingelheim International GmbH - Key offerings Exhibit 60: Boehringer Ingelheim International GmbH - Key customers Exhibit 61: Eli Lilly and Co. - Vendor overview Exhibit 62: Eli Lilly and Co. - Business segments Exhibit 63: Eli Lilly and Co. - Organizational developments Exhibit 64: Eli Lilly and Co. - Geographic focus Exhibit 65: Eli Lilly and Co. - Segment focus Exhibit 66: Eli Lilly and Co. - Key offerings Exhibit 67: Eli Lilly and Co. - Key customers Exhibit 68: H. Lundbeck AS - Vendor overview Exhibit 69: H. Lundbeck AS - Business segments Exhibit 70: H. Lundbeck AS - Organizational developments Exhibit 71: H. Lundbeck AS - Geographic focus Exhibit 72: H. Lundbeck AS - Key offerings Exhibit 73: H. Lundbeck AS - Key customers Exhibit 74: Johnson & Johnson Services Inc. - Vendor overview Exhibit 75: Johnson & Johnson Services Inc. - Business segments Exhibit 76: Johnson & Johnson Services Inc. - Organizational developments Exhibit 77: Johnson & Johnson Services Inc. - Geographic focus Exhibit 78: Johnson & Johnson Services Inc. - Segment focus Exhibit 79: Johnson & Johnson Services Inc. - Key offerings Exhibit 80: Johnson & Johnson Services Inc. - Key customers Exhibit 81: Mylan NV - Vendor overview Exhibit 82: Mylan NV - Product segments Exhibit 83: Mylan NV - Organizational developments Exhibit 84: Mylan NV - Geographic focus Exhibit 85: Mylan NV - Segment focus Exhibit 86: Mylan NV - Key offerings Exhibit 87: Mylan NV - Key customers Exhibit 88: Otsuka Holdings Co. Ltd. - Vendor overview Exhibit 89: Otsuka Holdings Co. Ltd. - Business segments Exhibit 90: Otsuka Holdings Co. Ltd. - Organizational developments Exhibit 91: Otsuka Holdings Co. Ltd. - Geographic focus Exhibit 92: Otsuka Holdings Co. Ltd. - Segment focus Exhibit 93: Otsuka Holdings Co. Ltd. - Key offerings Exhibit 94: Otsuka Holdings Co. Ltd. - Key customers Exhibit 95: Pfizer Inc. - Vendor overview Exhibit 96: Pfizer Inc. - Business segments Exhibit 97: Pfizer Inc. - Organizational developments Exhibit 98: Pfizer Inc. - Geographic focus Exhibit 99: Pfizer Inc. - Segment focus Exhibit 100: Pfizer Inc. - Key offerings Exhibit 101: Pfizer Inc. - Key customers Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers Exhibit 108: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 109: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 110: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 111: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 112: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 114: Validation techniques employed for market sizing Exhibit 115: Definition of market positioning of vendors

AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., H. Lundbeck AS, Johnson & Johnson Services Inc., Mylan NV, Otsuka Holdings Co. Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.